Logo

American Heart Association

  2
  0


Final ID: 4141743

Lipoprotein(a) and Outcomes After Coronary Angiography

Abstract Body (Do not enter title and authors here): Background: Lipoprotein(a) [Lp(a)] is a potent risk factor for coronary artery disease (CAD) with novel Lp(a)-lowering therapeutics under investigation. Data regarding implications of elevated Lp(a) among patients undergoing coronary angiography are limited. We aimed to assess (i) the association between Lp(a) levels and angiographic characteristics of CAD and (ii) whether Lp(a) levels predict adverse angiographic and clinical outcomes after index coronary angiogram.

Methods: Patients who underwent coronary angiography and Lp(a) measurement between 2000-2023 were classified into four Lp(a) risk groups: normal (<75 nmol/L), intermediate (75-124 nmol/L), high (125-174 nmol/L), and very high (≥175 nmol/L). Angiographic characteristics (severity, burden, Gensini score—a continuous measure of angiographic CAD burden) and future outcomes starting 3 months after index angiogram (repeat angiogram, revascularization, in-stent restenosis [ISR], heart failure [HF], and all-cause mortality) were analyzed by Lp(a) risk category using Cox proportional hazard models adjusted for age, sex, and race.

Results: Among 5,118 patients (26.5% female; median [IQR] age 64 [55-74]; 84.9% White), 3,138 (61.3%) had normal Lp(a) levels, 543 (10.6%) intermediate, 464 (9.1%) high, and 973 (19%) very high. Compared to normal Lp(a) levels, very high Lp(a) was associated with obstructive CAD (adjusted odds ratio [AOR], 1.50; 95%CI, 1.16-1.94), multi-vessel disease (AOR,1.79; 95%CI, 1.39-2.30), left-main disease (AOR, 1.80; 95%CI, 1.33-2.45), and a 13.9-point increase in the Gensini score (P<.001). Over a mean follow-up of 11.01±7.58 years, patients with very high Lp(a) were significantly more likely to undergo a repeat angiogram (adjusted hazard ratio [AHR], 1.22; 95%CI, 1.09-1.36), revascularization (AHR, 1.40; 95%CI, 1.19-1.64), and ISR (AHR, 1.34; 95%CI, 1.10-1.63). However, no increased risk of HF was observed (P>.05). The risk of mortality was 17% higher in the very high Lp(a) group (95%CI, 1.04-1.32). These trends persisted even after adjusting for baseline CAD burden (Figure).

Conclusion: Very high Lp(a) levels are associated with increased burden and severity of CAD and are strongly predictive of future angiographic and clinical outcomes.
  • Supriami, Kelvin  ( Massachusetts General Hospital, Harvard Medical School , Boston , Massachusetts , United States )
  • Faaborg-andersen, Christian  ( Massachusetts General Hospital, Harvard Medical School , Boston , Massachusetts , United States )
  • Tello, Jose  ( Broad Institute of MIT and Harvard , Boston , Massachusetts , United States )
  • Cho, So Mi Jemma  ( Broad Institute of MIT and Harvard , Boston , Massachusetts , United States )
  • Pomerantsev, Eugene  ( Massachusetts General Hospital, Harvard Medical School , Boston , Massachusetts , United States )
  • Ellinor, Patrick  ( Massachusetts General Hospital, Harvard Medical School , Boston , Massachusetts , United States )
  • Honigberg, Michael  ( Massachusetts General Hospital, Harvard Medical School , Boston , Massachusetts , United States )
  • Fahed, Akl  ( Massachusetts General Hospital, Harvard Medical School , Boston , Massachusetts , United States )
  • Author Disclosures:
    Kelvin Supriami: DO NOT have relevant financial relationships | Christian Faaborg-Andersen: DO NOT have relevant financial relationships | Jose Tello: DO NOT have relevant financial relationships | So Mi Jemma Cho: No Answer | Eugene Pomerantsev: No Answer | Patrick Ellinor: DO have relevant financial relationships ; Research Funding (PI or named investigator):Bayer AG:Active (exists now) ; Research Funding (PI or named investigator):Pfizer:Active (exists now) ; Research Funding (PI or named investigator):BMS:Active (exists now) ; Research Funding (PI or named investigator):Novo Nordisk:Active (exists now) ; Consultant:Bayer AG:Active (exists now) | Michael Honigberg: DO have relevant financial relationships ; Advisor:Miga Health:Active (exists now) ; Research Funding (PI or named investigator):Novartis:Expected (by end of conference) ; Consultant:Comanche Biopharma:Past (completed) ; Research Funding (PI or named investigator):Genentech:Active (exists now) | Akl Fahed: No Answer
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:
More abstracts on this topic:
A Biomarker Based on Aneurysm Wall Enhancement and Blood Gene Expression to Identify Symptomatic Intracranial Aneurysms

Veeturi Sricharan, Poppenberg Kerry, Jaikumar Vinay, Pinter Nandor, Levy Elad, Siddiqui Adnan, Tutino Vincent

A Two-year Longitudinal Investigation of Lipoprotein Particle Profile as Cardiometabolic Risk Biomarkers in Family Caregivers of Adult Patients with Cancer

Lee Lena, Shamburek Robert, Son Elisa H, Wallen Gwenyth, Yang Li, Tuason Ralph, Gerrard Chantal, Tsai Thomas, Kim Youngmee

More abstracts from these authors:
Racial Disparities in Low-Density Lipoprotein Cholesterol Control and Lipoprotein(a) Testing Among Young Adult Women with Severe Hyperlipidemia

Jowell Amanda, Cho So Mi, Faaborg-andersen Christian, Yu Zhi, Natarajan Pradeep, Honigberg Michael, Harrington Colleen

An Integrated Germline and Somatic Genomic Model Improves Risk Prediction for Coronary Artery Disease

Kim Min Seo, Zhang Rufan, Liu Zhaoqi, A Yunga, Ellinor Patrick, Natarajan Pradeep, Wang Minxian, Fahed Akl, Yang Xiong, Uddin Md Mesbah, Nakao Tetsushi, Cho So Mi Jemma, Koyama Satoshi, Zhu Xinyu, Xu Tingfeng, Reeskamp Laurens

You have to be authorized to contact abstract author. Please, Login
Not Available